Danaher Corporation (NYSE:DHR) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Danaher Corporation (NYSE:DHR) have earned a consensus rating of “Moderate Buy” from the twenty research firms that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $247.6087.

Several equities analysts have issued reports on DHR shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Friday, June 27th. Barclays reiterated an “overweight” rating and issued a $225.00 price objective (up previously from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Scotiabank upgraded Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research report on Friday, July 11th. Finally, TD Cowen lifted their price objective on Danaher from $240.00 to $248.00 and gave the company a “buy” rating in a research report on Wednesday, April 23rd.

Institutional Investors Weigh In On Danaher

A number of institutional investors have recently made changes to their positions in the stock. Evergreen Capital Management LLC grew its stake in shares of Danaher by 12.8% during the second quarter. Evergreen Capital Management LLC now owns 3,920 shares of the conglomerate’s stock worth $776,000 after purchasing an additional 445 shares during the period. Headlands Technologies LLC grew its stake in shares of Danaher by 27.0% during the second quarter. Headlands Technologies LLC now owns 69,406 shares of the conglomerate’s stock worth $13,710,000 after purchasing an additional 14,766 shares during the period. 44 Wealth Management LLC grew its stake in shares of Danaher by 7.8% during the second quarter. 44 Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $250,000 after purchasing an additional 92 shares during the period. Duquesne Family Office LLC acquired a new position in Danaher in the second quarter valued at about $4,879,000. Finally, MUFG Securities EMEA plc grew its stake in Danaher by 4.4% in the second quarter. MUFG Securities EMEA plc now owns 44,884 shares of the conglomerate’s stock valued at $8,867,000 after acquiring an additional 1,885 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Price Performance

Danaher stock opened at $210.84 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The company has a market capitalization of $150.97 billion, a PE ratio of 44.86, a price-to-earnings-growth ratio of 2.94 and a beta of 0.73. Danaher has a one year low of $171.00 and a one year high of $279.90. The business has a 50 day simple moving average of $199.94 and a 200 day simple moving average of $199.54.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping the consensus estimate of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%. Danaher’s revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the company earned $1.72 EPS. On average, sell-side analysts forecast that Danaher will post 7.63 EPS for the current fiscal year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.